24 items6 sources0 stocks
GlobeNewswire-Sep 1, 11:30 AM
Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)（摘要待生成）
The Motley Fool-Sep 1, 11:06 AM
Billionaire Stanley Druckenmiller Kicked Micron to the Curb in the Second Quarter in Favor of an AI Superstar That's Gained 13,700% Since Its IPO
Billionaire Stanley Druckenmiller Kicked Micron to the Curb in the Second Quarter in Favor of an AI Superstar That's Gained 13,700% Since Its IPO（摘要待生成）
GlobeNewswire-Sep 1, 11:02 AM
Ocugen Announces First Patient Dosed in Phase 3 Registrational Trial of OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
Ocugen Announces First Patient Dosed in Phase 3 Registrational Trial of OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration（摘要待生成）